171 related articles for article (PubMed ID: 37335754)
1. Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada.
Buchan SA; Chung H; To T; Daneman N; Guttmann A; Kwong JC; Murti M; Aryal G; Campigotto A; Chakraborty P; Gubbay J; Karnauchow T; Katz K; McGeer AJ; Dayre McNally J; Mubareka S; Richardson D; Richardson SE; Smieja M; Zahariadis G; Deeks SL
J Pediatric Infect Dis Soc; 2023 Jul; 12(7):421-430. PubMed ID: 37335754
[TBL] [Abstract][Full Text] [Related]
2. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Hospitalization for Respiratory Syncytial Virus Infection amongst Children in Ontario, Canada: A Population-Based Study Using Validated Health Administrative Data.
Pisesky A; Benchimol EI; Wong CA; Hui C; Crowe M; Belair MA; Pojsupap S; Karnauchow T; O'Hearn K; Yasseen AS; McNally JD
PLoS One; 2016; 11(3):e0150416. PubMed ID: 26958849
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.
Papenburg J; Defoy I; Massé E; Caouette G; Lebel MH
J Pediatric Infect Dis Soc; 2021 Apr; 10(3):237-244. PubMed ID: 32530035
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Cohort Study on Infant Respiratory Tract Infection Hospitalizations and Recurrent Wheeze and Asthma Risk: Impact of Respiratory Syncytial Virus.
van Wijhe M; Johannesen CK; Simonsen L; Jørgensen IM; ; Fischer TK
J Infect Dis; 2022 Aug; 226(Suppl 1):S55-S62. PubMed ID: 35426942
[TBL] [Abstract][Full Text] [Related]
6. Burden of illness associated with Respiratory Syncytial Virus (RSV)-related hospitalizations among adults in Ontario, Canada: A retrospective population-based study.
Mac S; Shi S; Millson B; Tehrani A; Eberg M; Myageri V; Langley JM; Simpson S
Vaccine; 2023 Aug; 41(35):5141-5149. PubMed ID: 37422377
[TBL] [Abstract][Full Text] [Related]
7. Inpatient burden of respiratory syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019-2022.
Wick M; Poshtiban A; Kramer R; Bangert M; Lange M; Wetzke M; Damm O
Influenza Other Respir Viruses; 2023 Nov; 17(11):e13211. PubMed ID: 38019702
[TBL] [Abstract][Full Text] [Related]
8. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
9. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
10. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
[TBL] [Abstract][Full Text] [Related]
11. The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: A semi-parametric, meta-regression approach.
Antillón M; Li X; Willem L; Bilcke J; ; Jit M; Beutels P
PLoS Med; 2023 Jul; 20(7):e1004250. PubMed ID: 37459352
[TBL] [Abstract][Full Text] [Related]
12. The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015.
Hardelid P; Verfuerden M; McMenamin J; Smyth RL; Gilbert R
Euro Surveill; 2019 Jan; 24(1):. PubMed ID: 30621817
[TBL] [Abstract][Full Text] [Related]
13. Respiratory Syncytial Virus-Associated Hospitalizations in Children: A 10-Year Population-Based Analysis in Finland, 2008-2018.
Uusitupa E; Waris M; Vuorinen T; Heikkinen T
Influenza Other Respir Viruses; 2024 Mar; 18(3):e13268. PubMed ID: 38477388
[TBL] [Abstract][Full Text] [Related]
14. Incidence of respiratory syncytial virus bronchiolitis in hospitalized infants born at 33-36 weeks of gestational age compared with those born at term: a retrospective cohort study.
Greenberg D; Dagan R; Shany E; Ben-Shimol S; Givon-Lavi N
Clin Microbiol Infect; 2020 Feb; 26(2):256.e1-256.e5. PubMed ID: 31181285
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
16. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children.
Madhi SA; Kuwanda L; Cutland C; Klugman KP
J Clin Virol; 2006 Jul; 36(3):215-21. PubMed ID: 16678480
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
18. Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023.
Fitzpatrick T; Buchan SA; Mahant S; Fu L; Kwong JC; Stukel TA; Guttmann A
JAMA Netw Open; 2024 Jun; 7(6):e2416077. PubMed ID: 38861259
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
20. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
